31 2 Outcome mean (SD) N/A 46.2 (22.2) I:68.6 (13.6), II:70.7 (15.4), p=0.624 At diagnosis: I:83.3 (30.3), II:78.0 (29.1) 3m: I:53.4 (18.6) 1y: I:69.0 (24.7), II:46.6 (29.1) 8y: I:66.7 (24.0) 33.1 (16.1) 6m: I:64.0 (11.0), II:64.0 (10.2) 12m: I:68.5 (10.6), II:71.0 (9.5), p=0.490 I: p=0.004 II: p=0.036 I:67.3 (16.9), II:73.9 (19.6), p=0.036 T2: III:72.6 (17.9), IV:73.1 (17.6), p=0.888 T3/T4: III:57.3 (20.2), IV:76.1 (14.1), p=0.001 I:87.5 (1.3), II:86.7 (1.7), p=0.37 Timing of assessment in m (range) N/A <3-24, mean 30 6 3, 12, and 96 27.6 (12-48) 1-3 y: 24 >3 y: 10 6 and 12 >12 I: med. 44.4 (12-144) II: med. 38.4 (24-120) Treatment (n) N/A Mandibular res., PMMF rec., PORT(46), POCRT(19) Res. with MRND, rec. with classical ALT perforator(I:27) or chimerical ALT perforator flap(II:21) FF rec. (I:14, II:18), ND (I:20, II:25), PORT (I:9, II:16) Mandible res., fibula FF rec. TG(II:16), PG (I:46, II:5), rec.(I:46, II:21), PO(C)RT(I:17, II:6) Maxillectomy or mandibulectomy (I:30, II:42, III:36, IV:49), ND (I:68, II:71, III:77, IV:62), rec. (RFFF(48), ATF(9), FOMF(5)), PORT(I:12, II:12, III:6, IV:18), Neo-adj. CRT (47) Res., flap rec. (I:6, II:12), PO(C)RT(I:8, II:16) N stage (n) N/A N0: 48 N1: 5 N2: 12 N0: I:18, II:13 N1: I:5, II:6 N2: I:4, II:2 N/A N/A N/A N/A N0: I:16, II:32 N1: I:3, II:6 N2: I:2, II:4 T stage (n) N/A T1: 14 T2: 35 T3: 3 T4: 13 T1: I:8, II:9 T2: I:18, II:10 T3: I:1, II:1 T4: II:1 T1-2: I:22, II:12 T3-4: I:8, II:13 T1-2: 10 T3-4: 23 T1-2: I:25, II:13 T3-4: I:21, II:8 T2: I:53, II:39 T3-4: I:15, II:32 T1-2: I:16, II:32 T3-4: I:5, II:10 Site (n) N/A A(12), B(42), RMT (4), T(7) B(I:27, II:21) G (I:13, II:8), T (I:7, II:13), other (I:10, II:4) A(13), B(7), FOM(9), T(5) T(67) B and FOM and RMT and P(71), T(68) T(63) Age mean (SD) (range) in y N/A 50.5 (30-60) I:46.9 (9.2) II:47.4 (9.8) I:57.7 (35-81) II:59.5 (35-90) Med. 53.4 (2865) Med. 56.2 (3374) % under 70: 24% I:28%, II:20% T2: III:85%, IV:90% T3-4: III:88%, IV:83% I:34.0 (5.2) (22-40) II:58.9 (7.4) (42-74) n (%male) 30 65 (85) I:27 (96) II:21 (95) I:30 (57) II:25 (56) 34 (74) 67 (67) I:46 (72) II:21 (76) 139 (65) I:68 (63), II:71 (66) T2: III:53 (57), IV:39 (67) T3-4: III:24 (79), IV:23 (65) I:21 (43) II:42 (43) Subgroups N/A N/A I:classic ALTFF II:chimeric ALTFF I:longterm survivors (8y) II:nonsurvivors (<8y) N/A I:RFFF II:ALTFF I:tongue II:other III:no rec. IV:rec I:≤ 40 years II:≥ 40 years Table 1 (continued) Type C C, P C, R L, P L, R L, P C, P C Location PK IN CHN CHN CHN CHN CHN CHN Author 19. Vakil et al. (2012) 20. Vora et al. (2017) 21. Wu et al. (2020) 22. Yan et al. (2017) 23. Yang et al. (2014) 24. Yuan et al. (2016) 25. Yue et al. (2018) 26. Zhang et al. (2013)

RkJQdWJsaXNoZXIy MjY0ODMw